trending Market Intelligence /marketintelligence/en/news-insights/trending/3d7tdqx1KsezZCqzR6ZBcQ2 content esgSubNav
In This List

Quidel's antepartum diagnostic test gets US FDA clearance

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Quidel's antepartum diagnostic test gets US FDA clearance

The U.S. Food and Drug Administration granted 510(k) clearance to Quidel Corp.'s Solana GBS Assay test, which detects Group B streptococcus in women nearing childbirth.

The bacteria can cause infections leading to sepsis, pneumonia and meningitis in newborns. Deafness and developmental disabilities may also result from the transmission Group B streptococcus at delivery.